Cleansing composition comprising a nonionic / cationic surfactant mixture

Information

  • Patent Grant
  • 11052031
  • Patent Number
    11,052,031
  • Date Filed
    Friday, August 14, 2020
    3 years ago
  • Date Issued
    Tuesday, July 6, 2021
    2 years ago
Abstract
An aqueous cleansing composition comprising a cationic surfactant, a nonionic surfactant, and a thickener comprising an alkoxylated methyl glucose ether, wherein a weight ratio of cationic surfactant to nonionic surfactant is greater than 0.9:1. The combination of the cationionic:nonionic surfactant ratio with the alkoxylated methyl glucose ether thickener provides the composition with cold weather stability. Cold weather stability is observed when the composition remains transparent after cold storage.
Description
BACKGROUND

Cationic surfactants can provide antibacterial properties to a cleansing composition. When cationic surfactants are mixed with nonionic surfactants, there is generally a need to use thickeners to increase the viscosity to a level that is expected by consumers for a cleansing composition, such as a liquid hand soap or body wash. While polyacrylate thickeners can increase the viscosity, they can make the cleansing composition opaque or translucent. It would be desirable to provide a cleansing composition containing cationic and nonionic surfactants that is transparent.


BRIEF SUMMARY

An aqueous cleansing composition comprising a cationic surfactant, a nonionic surfactant, and a thickener comprising an alkoxylated methyl glucose ether, wherein a weight ratio of cationic surfactant to nonionic surfactant is greater than 0.9:1.


The combination of the cationionic:nonionic surfactant ratio with the alkoxylated methyl glucose ether thickener provides the composition with cold weather stability. Cold weather stability is observed when the composition remains transparent after cold storage.


Further areas of applicability of the present invention will become apparent from the detailed description provided hereinafter. It should be understood that the detailed description and specific examples, while indicating the preferred embodiment of the invention, are intended for purposes of illustration only and are not intended to limit the scope of the invention.







DETAILED DESCRIPTION

The following description of the preferred embodiment(s) is merely exemplary in nature and is in no way intended to limit the invention, its application, or uses.


As used throughout, ranges are used as shorthand for describing each and every value that is within the range. Any value within the range can be selected as the terminus of the range. In addition, all references cited herein are hereby incorporated by referenced in their entireties. In the event of a conflict in a definition in the present disclosure and that of a cited reference, the present disclosure controls.


Unless otherwise specified, all percentages and amounts expressed herein and elsewhere in the specification should be understood to refer to percentages by weight. The amounts given are based on the active weight of the material.


For the purpose of calculating a cationic surfactant to nonionic surfactant ratio, cationic surfactant does not include a cationic antibacterial agent selected from the group consisting of benzalkonium chloride, benzethonium chloride, and mixtures thereof. While these materials may function as a cationic surfactant, they are not included in the calculation.


Transparency is defined as the ability to read 12-point font through the composition contained in a 4 oz clear, glass sample bottle of 4 cm thickness. Transparency is measured after 24 hours at 4.5° C.


Viscosity is measured using a Brookfield RVT viscometer with spindle #5 at 25 rpm at 25° C.


The composition includes a cationic surfactant. The cationic surfactant can be any cationic surfactant, but it excludes the cationic bacterial agent for weight ratio calculation. In certain embodiments, the cationic surfactant comprises a quaternary ammonium alkyl salt. The quaternary ammonium alkyl salt can be an alkyltrimethylammonium salts. The salt can be a halide, such as chloride or bromide, or a methosulfate. The alkyl can be a C8-C24 alkyl or a C14-C18 alkyl. In certain embodiments, the cationic surfactant is cetyltrimethylammonium chloride.


In certain embodiments, the cationic surfactant is present in an amount of 0.1 to 20 weight % of the composition. In other embodiments, the amount is 0.1 to 10, 0.1 to 5, 0.5 to 10, 0.5 to 5, 1 to 5, or 2 to 4 weight %.


The composition includes a nonionic surfactant. The nonionic surfactants can be any nonionic surfactant. Nonionic surfactants include, but are not limited to, amine oxides, fatty acid amides, ethoxylated fatty alcohols, block copolymers of polyethylene glycol and polypropylene glycol, glycerol alkyl esters, alkyl polyglucosides, polyoxyethylene glycol octylphenol ethers, sorbitan alkyl esters, polyoxyethylene glycol sorbitan alkyl esters, and mixtures thereof. Examples of amine oxides include, but are not limited to, laurylamidopropyl dimethylamine oxide, myristylamidopropyl dimethylamine oxide, and mixtures thereof. Examples of fatty acid amides include, but are not limited to, cocomonoethanolamide, lauramide monoethanolamide, cocodiethanolamide, and mixtures thereof.


In certain embodiments, the nonionic surfactant is a combination of an amine oxide and a fatty acid amide. In certain embodiments, the amine oxide is a mixture of laurylamidopropyl dimethylamine oxide and myristylamidopropyl dimethylamine oxide. In certain embodiments, the nonionic surfactant is a combination of lauryl/myristylamidopropyl dimethylamine oxide and cocomonoethanolamide.


In certain embodiments, the nonionic surfactant is present in an amount of 0.1 to 20 weight % of the composition. In other embodiments, the amount is 0.1 to 10, 0.1 to 5, 0.5 to 10, 0.5 to 5, or 0.5 to 3 weight %.


The composition has a cationic:nonionic weight ratio greater than 0.9:1. Optionally, the ratio is at least 1:1.


In certain embodiments, the composition does not contain an anionic surfactant.


The composition also includes a thickener comprising an alkoxylated methyl glucose ether. The alkoxylation can be ethoxylated and/or propoxylated. In certain embodiments, it is ethoxylated. The degree of alkoxylation can be any degree that provides thickening. In certain embodiments, the degree of alkoxylation is 100 to 200. In certain embodiments, the alkoxylation is 120 to 150. The alkoxylated methyl glucose ether can be esterified with fatty acid. In certain embodiments, the alkoxylated methyl glucose ether at least one of an alkoxylated methyl glucose dioleate, an alkoxylated methyl glucose trioleate, alkoxylated methyl glucose distearate. In certain embodiments, the alkoxylated methyl glucoside is at least one of PEG-120 methyl glucose dioleate, PEG-120 methyl glucose trioleate, PEG-120 methyl glucose distearate. In certain embodiments, the alkoxylated methyl glucose ether is PEG-120 methyl glucose dioleate.


The thickener can be present in any amount to provide any desired viscosity level. In certain embodiments, the thickener is present in an amount of 0.1 to 2 weight % of the composition. In other embodiments, the amount is 0.1 to 1, 0.2 to 1, 0.3 to 1, 0.4 to 1, 0.1 to 0.9, 0.1 to 0.8, 0.1 to 0.7, 0.3 to 0.8, or 0.4 to 0.8 weight %. In one embodiment, the amount is 0.4 to 0.7 weight %. In certain embodiments, the viscosity is at least 1000 mPas. In other embodiments, the viscosity is at least 2000, at least 3000, or at least 4000 mPas. In certain embodiments, the viscosity is 1000 to 20000, 3000 to 6000, or 3500 to 5000 mPas.


In certain embodiments, the composition does not include a polyacrylate thickener.


The composition can include a cationic antibacterial agent selected from the group consisting of benzalkonium chloride, benzethonium chloride, and mixtures thereof. In certain embodiments, the composition includes benzalkonium chloride. These cationic antibacterial agents can be included in their regulatory amount, which can be 0.13 weight %.


The composition is aqueous. In certain embodiments, water can be included in an amount of 70 to 95 weight % of the composition. In other embodiments, the amount of water is 90 to 95 weight %.


In certain embodiments, the composition can further include salt, such as sodium chloride to assist in increasing viscosity at upper ranges of viscosity. In certain embodiments, the salt is present at 0.1 to 1.2 weight % of the composition. In certain embodiments, the amount is about 0.6 weight %.


The cleansing compositions can be used to cleanse skin by washing skin with the cleansing composition and optionally rinsing with water.


Examples

The examples and comparative examples are made by mixing of the materials. The compositions are shown in Tables 1 and 2 below. The examples list the cationic:nonionic surfactant ratio. The viscosity and the transparency after storage at 4.5° C. are measured.












TABLE 1





Material
Example 1
Example 2
Example 3







Deionized Water and minors
QS
QS
QS


Lauryl/Myristylamidopropyl
1.68
1.68
0.6


dimethylamine oxide


Cocomonoethanolamide
0.92
1.02
0.4


Cetrimonium chloride
2.75
2.5
3


Benzalkonium chloride
0.13
0.13
0.13


PEG 120 Methyl Glucose
0.54
0.6
0.54


Dioleate


Glycerin
2
2
2


Sodium chloride
0.62
0.62
0.62


Cationic:Nonionic
1.06:1
0.92:1
3:1


surfactant ratio


Transparency after
Clear
Clear
Clear


cold storage


Viscosity (mPas)
4340
4740
5210




















TABLE 2





Material
Comparative A
Comparative B
Comparative C
Comparative D







Deionized Water and minors
QS
QS
QS
QS


Lauryl/Myristylamidopropyl
1.68
1.51
1.68
2


dimethylamine oxide


Cocomonoethanolamide
1.1
1.12
1.12
1


Cetrimonium chloride
2.25
2.25
2.25
1


Benzalkonium chloride
0.13
0.13
0.13
0.13


PEG 120 Methyl Glucose
0.66
0.66
0.54
0.6


Dioleate


Glycerin
2
2
2
2


Sodium chloride
0.62
0.62
0.62
0.62


Cationic:Nonionic
0.81:1
0.85:1
0.80:1
0.33:1


surfactant ratio


Transparency after
Hazy
Hazy
Hazy
Hazy


cold storage


Viscosity (mPas)
4600
4000
4340
4470









As can be seen in the examples, the combination of the PEG-120 methyl glucose dioleate and the cationic:nonionic surfactant ratio provides a composition that is clear after cold storage and has a desired viscosity over 4000 mPas. When PEG-120 methyl glucose dioleate is present in all compositions, a desired viscosity is obtained, but when the cationic:nonionic surfactant ratio is less than 0.9 in the comparative examples, the composition is hazy after cold storage.

Claims
  • 1. An aqueous cleansing composition comprising: a) from 2.5 to 3 weight % of the composition of a cationic surfactant which is cetyltrimethylammonium chloride;b) from 0.5 to 10 weight % of the composition of a nonionic surfactant which is a mixture of: i) lauryl/myristyl amidopropyl dimethylamine oxide; andii) cocomonoethanolamide; andc) from 0.2 to 1 weight % of the composition of a thickener which is PEG-120 methyl glucose dioleate.
  • 2. The cleansing composition of claim 1 further comprising a cationic antibacterial agent selected from the group consisting of benzalkonium chloride, benzethonium chloride, and mixtures thereof.
  • 3. The cleansing composition of claim 2, wherein the cationic antibacterial agent is benzalkonium chloride present in an amount of about 0.13 weight % of the composition.
  • 4. The cleansing composition of claim 1, further comprising glycerin.
  • 5. The cleansing composition of claim 1, wherein glycerin is present in an amount of about 2 weight % of the composition.
  • 6. The cleansing composition of claim 1, wherein cetyl trimethyl ammonium chloride is present in an amount of about 2.75 weight % of the composition.
  • 7. The cleansing composition of claim 1, wherein the composition does not contain an anionic surfactant.
  • 8. The cleansing composition of claim 1, wherein an amount of water is 70 to 95 weight % of the composition.
  • 9. The cleaning composition of claim 1 further comprising a salt, optionally in an amount of 0.1 to 1.2 weight % of the composition.
  • 10. The cleansing composition of claim 1, wherein the composition does not contain a polyacrylate.
  • 11. The cleansing composition of claim 1, wherein the composition is transparent after 24 hours at 4.5° C.
  • 12. A method of cleansing skin comprising washing skin with the cleansing composition of claim 1, and optionally rinsing with water.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/448,183, filed on Jun. 21, 2019, which is a continuation of U.S. patent application Ser. No. 16/032,503, filed on Jul. 11, 2018, which is a continuation of U.S. patent application Ser. No. 15/049,089, filed on Feb. 21, 2016, now U.S. Pat. No. 10,179,100, which is a continuation of U.S. patent application Ser. No. 14/690,320, filed on Apr. 17, 2015, now U.S. Pat. No. 9,265,714, which claims the benefit under 35 U.S.C. § 365(c) of International Patent Application No. PCT/US2013/061801, filed Sep. 26, 2013, the entireties of which are incorporated herein by reference.

US Referenced Citations (42)
Number Name Date Kind
5290482 Marschner et al. Mar 1994 A
5326483 Halloran et al. Jul 1994 A
5641480 Vermeer Jun 1997 A
5661170 Chodosh Aug 1997 A
5723111 Glover Mar 1998 A
5725887 Martin et al. Mar 1998 A
5827870 Chodosh Oct 1998 A
5994383 Dyer et al. Nov 1999 A
6087400 Dyer et al. Jul 2000 A
6121224 Fonsny et al. Sep 2000 A
6306805 Bratescu et al. Oct 2001 B1
6488948 Danieli Dec 2002 B1
6566314 Murthy et al. May 2003 B1
6572846 Klein Jun 2003 B2
6616922 Taylor et al. Sep 2003 B2
7012048 Drovetskaya et al. Mar 2006 B2
7112559 Mayhall et al. Sep 2006 B1
7169193 Kleen Jan 2007 B2
7192601 Walker Mar 2007 B2
7754770 Curtis Jul 2010 B2
8193136 Taylor et al. Jun 2012 B2
8388991 Sondgeroth et al. Mar 2013 B2
8795641 Pan Aug 2014 B2
9084734 Collier et al. Jul 2015 B2
9232790 Moen et al. Jan 2016 B2
10119409 Charier et al. Nov 2018 B2
20020031487 Klein Mar 2002 A1
20020169099 Knox et al. Nov 2002 A1
20030022941 Taylor Jan 2003 A1
20050147575 Muller Jul 2005 A1
20050189377 Lanzendorfer et al. Sep 2005 A1
20050198747 Emmerling et al. Sep 2005 A1
20070077221 Seigneurin et al. Apr 2007 A1
20070292383 Schepky et al. Dec 2007 A1
20080275113 Huetter et al. Nov 2008 A1
20090246163 Wahi Oct 2009 A1
20110237667 Loeffler et al. Sep 2011 A1
20130035396 Moen Feb 2013 A1
20140100288 DeSzalay Apr 2014 A1
20140170086 Pan et al. Jun 2014 A1
20160030319 Liu Feb 2016 A1
20180153786 De Szalay Jun 2018 A1
Foreign Referenced Citations (4)
Number Date Country
1032263 Sep 2000 EP
1465584 Oct 2004 EP
2010039291 Apr 2010 WO
2010127231 Nov 2010 WO
Non-Patent Literature Citations (9)
Entry
Mintel Record # 1245173, Jan. 2010.
Mintel Record # 1268395, Feb. 2010.
Mintel Record # 1371278, Jul. 2010.
Mintel Record # 686467, Apr. 2007.
Mintel Record # 721749, Jun. 2007.
Mintel Record # 766162, Sep. 2007.
Mintel Record # 768340, Sep. 2007.
Mintel Record # 822840, Nov. 2007.
Mintel Record # 928927, Jun. 2008.
Related Publications (1)
Number Date Country
20200368132 A1 Nov 2020 US
Continuations (5)
Number Date Country
Parent 16448183 Jun 2019 US
Child 16993330 US
Parent 16032503 Jul 2018 US
Child 16448183 US
Parent 15049089 Feb 2016 US
Child 16032503 US
Parent 14690320 Apr 2015 US
Child 15049089 US
Parent PCT/US2013/061801 Sep 2013 US
Child 14690320 US